Subtopic Deep Dive

Therapeutic Targeting of FGF Pathways
Research Guide

What is Therapeutic Targeting of FGF Pathways?

Therapeutic Targeting of FGF Pathways involves pharmacological modulation of fibroblast growth factor (FGF) signaling and FGF receptors (FGFRs) to treat diseases including cancer, obesity, and fibrosis.

FGF/FGFR signaling regulates cellular proliferation, differentiation, and survival, making it a target for inhibitors in oncology and agonists like FGF21 in metabolic disorders (Xie et al., 2020, 806 citations). Clinical trials test FGFR inhibitors in tumors with FGFR alterations, while FGF21 analogs address diabetes (Kharitonenkov et al., 2005, 2053 citations; Helsten et al., 2015, 783 citations). Over 10 papers since 2015 detail resistance mechanisms and tissue regeneration applications.

Curated Papers

Key Challenges

Why It Matters

FGFR inhibitors show promise in cholangiocarcinoma and bladder cancer with FGFR fusions, as profiled in 4,853 tumors (Helsten et al., 2015). FGF21 analogs lower glucose uptake in adipocytes, offering diabetes therapies (Kharitonenkov et al., 2005). FGF2 supports tissue regeneration via RAS/MAPK pathways (Yun et al., 2010). Targeting reduces fibrosis by modulating fibroblast ECM production (Kendall and Feghali-Bostwick, 2014). Babina and Turner (2017) highlight challenges in overcoming resistance for broader clinical use.

Key Research Challenges

FGFR Inhibitor Resistance

Tumors develop resistance through FGFR mutations or bypass pathways, limiting long-term efficacy (Babina and Turner, 2017). Helsten et al. (2015) found FGFR alterations in 5% of cancers, but response rates drop post-treatment. Secondary sequencing identifies adaptive mechanisms requiring combination therapies.

FGF21 Delivery Barriers

FGF21's short half-life and renal clearance hinder systemic administration for obesity (Kharitonenkov et al., 2005). Analogs need engineering for stability without losing glucose-regulating potency. Clinical translation faces immunogenicity risks.

Fibrosis-Specific Targeting

Fibroblasts drive ECM deposition in fibrosis, but selective FGF inhibition avoids off-target effects on healthy tissue (Kendall and Feghali-Bostwick, 2014). Xie et al. (2020) note pathway redundancy complicates monotherapy. MSC-to-TAF transitions amplify signaling in tumors (Spaeth et al., 2009).

Essential Papers

Role of platelet-derived growth factors in physiology and medicine

Johanna Andræ, R Gallini, Christer Betsholtz · 2008 · Genes & Development · 2.4K citations

Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) have served as prototypes for growth factor and receptor tyrosine kinase function for more than 25 years. Studies of PDGFs and P...

FGF-21 as a novel metabolic regulator

Alexei Kharitonenkov, Tatiyana L. Shiyanova, Anja Köester et al. · 2005 · Journal of Clinical Investigation · 2.1K citations

Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a po...

Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?

Qing Chen, Peishun Shou, Changwen Zheng et al. · 2016 · Cell Death and Differentiation · 1.2K citations

Mesenchymal stem cells (MSCs), a non-hematopoietic stem cell population first discovered in bone marrow, are multipotent cells capable of differentiating into mature cells of several mesenchymal ti...

Fibroblasts in fibrosis: novel roles and mediators

Ryan T. Kendall, Carol A. Feghali-Bostwick · 2014 · Frontiers in Pharmacology · 1.0K citations

Fibroblasts are the most common cell type of the connective tissues found throughout the body and the principal source of the extensive extracellular matrix (ECM) characteristic of these tissues. T...

Biological Roles of Fibroblast Growth Factor-2*

Andréas Bikfalvi, Sharon Klein, Giuseppe Pintucci et al. · 1997 · Endocrine Reviews · 882 citations

I. Introduction II. Structure of FGF-2 III. Mechanisms of Action of FGF-2: Extra- and Intracellular Signaling A. Exogenous 18-kDa FGF-2 B. Endogenous 18-kDa FGF-2 and HMW FGF-2 IV. Release of FGF-2...

FGF/FGFR signaling in health and disease

Yangli Xie, Nan Su, Jing Yang et al. · 2020 · Signal Transduction and Targeted Therapy · 806 citations

Abstract Growing evidences suggest that the fibroblast growth factor/FGF receptor (FGF/FGFR) signaling has crucial roles in a multitude of processes during embryonic development and adult homeostas...

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

Teresa Helsten, Sheryl K. Elkin, Elisa Arthur et al. · 2015 · Clinical Cancer Research · 783 citations

Abstract Purpose: Molecular profiling may have prognostic and predictive value, and is increasingly used in the clinical setting. There are more than a dozen fibroblast growth factor receptor (FGFR...

Reading Guide

Foundational Papers

Start with Kharitonenkov et al. (2005) for FGF21 metabolic regulation (2053 citations); Andræ et al. (2008) for growth factor prototypes (2373 citations); Bikfalvi et al. (1997) for FGF2 mechanisms (882 citations). These establish signaling basics before therapeutic applications.

Recent Advances

Xie et al. (2020) for comprehensive FGF/FGFR roles (806 citations); Babina and Turner (2017) for cancer targeting advances (752 citations); Helsten et al. (2015) for tumor profiling (783 citations). These cover clinical translation and challenges.

Core Methods

FGFR inhibitors block kinase domains (Babina and Turner, 2017); FGF21 engineering for half-life extension (Kharitonenkov et al., 2005); sequencing for alterations (Helsten et al., 2015); pathway analysis via RAS/MAPK (Yun et al., 2010).

How PapersFlow Helps You Research Therapeutic Targeting of FGF Pathways

Discover & Search

Research Agent uses searchPapers and exaSearch to find FGF targeting papers like 'FGF/FGFR signaling in health and disease' (Xie et al., 2020), then citationGraph reveals 800+ citations linking to cancer applications, while findSimilarPapers uncovers resistance studies from Babina and Turner (2017).

Analyze & Verify

Analysis Agent applies readPaperContent to extract FGFR mutation frequencies from Helsten et al. (2015), verifies claims with CoVe chain-of-verification, and runs PythonAnalysis on citation data for statistical trends in obesity trials using Kharitonenkov et al. (2005); GRADE grading scores evidence strength for clinical translation.

Synthesize & Write

Synthesis Agent detects gaps in resistance mechanisms across Xie et al. (2020) and Babina and Turner (2017), flags contradictions in FGF21 efficacy; Writing Agent uses latexEditText, latexSyncCitations for FGFR pathway diagrams, and latexCompile to generate publication-ready reviews with exportMermaid for signaling cascades.

Use Cases

"Analyze FGFR mutation frequencies and inhibitor response rates from tumor sequencing data."

Research Agent → searchPapers('FGFR cancer sequencing') → Analysis Agent → readPaperContent(Helsten 2015) → runPythonAnalysis(pandas aggregation of mutation stats) → CSV export of verified response rates.

"Draft LaTeX review on FGF21 analogs for obesity therapeutics."

Synthesis Agent → gap detection(FGF21 papers) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(Kharitonenkov 2005) → latexCompile → PDF with synced bibliography.

"Find code for simulating FGF/FGFR signaling networks."

Research Agent → paperExtractUrls(FGF modeling papers) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis(matplotlib visualization of pathway dynamics).

Automated Workflows

Deep Research workflow scans 50+ FGF papers via searchPapers, structures reports on therapeutic targets with GRADE grading (e.g., FGFR inhibitors). DeepScan's 7-step chain analyzes resistance in Babina and Turner (2017) with CoVe checkpoints and Python verification. Theorizer generates hypotheses on FGF21 combinations from Kharitonenkov et al. (2005) and Xie et al. (2020).

Try Doxa for Therapeutic Targeting of FGF Pathways Research

Frequently Asked Questions

What defines therapeutic targeting of FGF pathways?

It encompasses drugs modulating FGF ligands or FGFRs to treat cancer, metabolic diseases, and fibrosis, as reviewed in Xie et al. (2020).

What are key methods for FGF targeting?

FGFR tyrosine kinase inhibitors target fusions in cancer (Helsten et al., 2015); FGF21 analogs enhance glucose uptake for diabetes (Kharitonenkov et al., 2005).

What are landmark papers?

Kharitonenkov et al. (2005, 2053 citations) on FGF21; Xie et al. (2020, 806 citations) on FGFR signaling; Babina and Turner (2017, 752 citations) on cancer targeting.

What open problems exist?

Resistance to FGFR inhibitors via mutations (Babina and Turner, 2017); FGF21 stability for clinical use; selective fibrosis modulation without toxicity (Kendall and Feghali-Bostwick, 2014).